Michael Rogawski

Michael Rogawski's picture
Professor

Director, Institute for Neurotherapeutics Discovery
Associate Director, UC Davis CounterACT Center of Excellence

(916) 801-5714
rogawski@ucdavis.edu
Lab Webpage: 
http://mr.ucdavis.edu

The goal of Dr. Rogawski's research is to discover and develop improved treatments for neurological disorders, including epilepsy, migraine, traumatic brain injury and neurobehavioral disorders.

Education

1980 Ph.D., Pharmacology, Yale University

1980 M.D., Yale University School of Medicine

1974 B.A., Biophysics, magna cum laude, Amherst College

Professional Appointments

1982–1985 Resident, Fellow (Neurology) and Assistant Professor, Johns Hopkins University School of Medicine

1986–2006 Senior Investigator and Chief, Epilepsy Research Section, National Institute of Neurological Disorders and Stroke, National Institutes of Health

2008–present Special Government Employee, Peripheral and Central Nervous System Drugs Advisory Committee, Center for Drug Evaluation and Research, Food and Drug Administration

2012–2014 President, American Society for Experimental NeuroTherapeutics


Click Here to Access Laboratory Web Site


Selected Publications: 

Broomall E, Natale JE, Grimason M, Goldstein J, Smith CM, Chang C, Kanes S, Rogawski MA, Wainwright MS. Pediatric super-refractory status epilepticus treated with allopregnanolone. Ann Neurol, Accepted Article, 2014.

Chen CY, Matt L, Hell JW, Rogawski MA. Perampanel inhibition of AMPA receptor currents in cultured hippocampal neurons. PLoS One. 2014 Sep 17;9(9):e108021. doi: 10.1371/journal.pone.0108021. eCollection 2014. PubMed PMID: 25229608; PubMed Central PMCID: PMC4168215.

Fritsch B, Reis J, Gasior M, Kaminski RM, Rogawski MA. Role of GluK1 kainate receptors in seizures, epileptic discharges, and epileptogenesis. J Neurosci. 2014 Apr 23;34(17):5765-75. doi: 10.1523/JNEUROSCI.5307-13.2014. PubMed PMID: 24760837; PubMed Central PMCID: PMC3996208.

Zolkowska D, Dhir A, Krishnan K, Covey DF, Rogawski MA. Anticonvulsant potencies of the enantiomers of the neurosteroids androsterone and etiocholanolone exceed those of the natural forms. Psychopharmacology (Berl) 2014 Sep;231(17):3325-32. doi: 10.1007/s00213-014-3546-x. Epub 2014 Apr 5. PubMed PMID: 24705905; PubMed Central PMCID: PMC4134984.

Kaminski RM, Rogawski MA, Klitgaard H. The potential of antiseizure drugs and agents that act on novel molecular targets as antiepileptogenic treatments. Neurotherapeutics. 2014 Apr;11(2):385-400. doi: 10.1007/s13311-014-0266-1. PubMed PMID: 24671870; PubMed Central PMCID: PMC3996125.

Inceoglu B, Zolkowska D, Yoo HJ, Wagner KM, Yang J, Hackett E, Hwang SH, Lee KS, Rogawski MA, Morisseau C, Hammock BD. Epoxy fatty acids and inhibition of the soluble epoxide hydrolase selectively modulate GABA mediated neurotransmission to delay onset of seizures. PLoS One. 2013 Dec 11;8(12):e80922. doi: 10.1371/journal.pone.0080922. eCollection 2013. PubMed PMID: 24349022; PubMed Central PMCID: PMC3862847.

Rogawski MA, Loya CM, Reddy K, Zolkowska D, Lossin C. Neuroactive steroids for the treatment of status epilepticus. Epilepsia. 2013 Sep;54 Suppl 6:93-8. doi: 10.1111/epi.12289. Review. PubMed PMID: 24001085; PubMed Central PMCID:
PMC3772544.

Wilcox KS, Dixon-Salazar T, Sills GJ, Ben-Menachem E, White HS, Porter RJ, Dichter MA, Moshé SL, Noebels JL, Privitera MD, Rogawski MA. Issues related to development of new antiseizure treatments. Epilepsia. 2013 Aug;54 Suppl 4:24-34. doi: 10.1111/epi.12296. Review. PubMed PMID: 23909851; PubMed Central PMCID:
PMC3947404.

Galanopoulou AS, Kokaia M, Loeb JA, Nehlig A, Pitkänen A, Rogawski MA, Staley KJ, Whittemore VH, Dudek FE. Epilepsy therapy development: technical and methodologic issues in studies with animal models. Epilepsia. 2013 Aug;54 Suppl 4:13-23. doi: 10.1111/epi.12295. Review. PubMed PMID: 23909850; PubMed Central PMCID: PMC3747731.

Bröer S, Zolkowska D, Gernert M, Rogawski MA. Proconvulsant actions of intrahippocampal botulinum neurotoxin B in the rat. Neuroscience. 2013 Nov 12;252:253-61. doi: 10.1016/j.neuroscience.2013.07.050. Epub 2013 Jul 29. PubMed
PMID: 23906638.

Dhir A, Zolkowska D, Rogawski MA. Seizure protection by intrapulmonary delivery of midazolam in mice. Neuropharmacology. 2013 Jun 15;73C:425-431. doi: 10.1016/j.neuropharm.2013.06.002.

Gasior M, Tang R, Rogawski MA. Long-lasting Attenuation of Amygdala-Kindled Seizures after Convection- Enhanced Delivery of Botulinum Neurotoxins A and B into the Amygdala in Rats. J Pharmacol Exp Ther. 2013 Jun 14.

Rogawski MA. The intrinsic severity hypothesis of pharmacoresistance to antiepileptic drugs. Epilepsia. 2013 May;54 Suppl 2:33-40.

Rogawski MA, Hanada T. Preclinical pharmacology of perampanel, a selective non-competitive AMPA receptor antagonist. Acta Neurol Scand Suppl. 2013;(197):19-24.

Rogawski MA. AMPA receptors as a molecular target in epilepsy therapy. Acta Neurol Scand Suppl. 2013;(197):9-18.

Devinsky O, Vezzani A, Najjar S, De Lanerolle NC, Rogawski MA. Glia and epilepsy: excitability and inflammation. Trends Neurosci. 2013 Mar;36(3):174-84.

Löscher W, Rogawski MA. How theories evolved concerning the mechanism of action of barbiturates. Epilepsia. 2012 Dec;53 Suppl 8:12-25.

Porter RJ, Dhir A, Macdonald RL, Rogawski MA. Mechanisms of action of antiseizure drugs. Handb Clin Neurol. 2012;108:663-81.

Lossin C, Nam TS, Shahangian S, Rogawski MA, Choi SY, Kim MK, Sunwoo IN. Altered fast and slow inactivation of the N440K Nav1.4 mutant in a periodic paralysis syndrome. Neurology. 2012 Sep 4;79(10):1033-40.

Cao Z, Hammock BD, McCoy M, Rogawski MA, Lein PJ, Pessah IN. Tetramethylenedisulfotetramine alters Ca²⁺ dynamics in cultured hippocampal neurons: mitigation by NMDA receptor blockade and GABA(A) receptor-positive modulation. Toxicol Sci. 2012 Dec;130(2):362-72.

French JA, Krauss GL, Biton V, Squillacote D, Yang H, Laurenza A, Kumar D, Rogawski MA. Adjunctive perampanel for refractory partial-onset seizures: randomized phase III study 304. Neurology. 2012 Aug 7;79(6):589-96.

Rogawski MA. Migraine and Epilepsy—Shared Mechanisms within the Family of Episodic Disorders. In: Noebels JL, Avoli M, Rogawski MA, Olsen RW, Delgado-Escueta AV, editors. Jasper's Basic Mechanisms of the Epilepsies [Internet]. 4th edition. Bethesda (MD): National Center for Biotechnology Information (US); 2012.

Reddy DS, Rogawski MA. Neurosteroids — Endogenous Regulators of Seizure Susceptibility and Role in the Treatment of Epilepsy. In: Noebels JL, Avoli M, Rogawski MA, Olsen RW, Delgado-Escueta AV, editors. Jasper's Basic Mechanisms of the Epilepsies [Internet]. 4th edition. Bethesda (MD): National Center for Biotechnology Information (US); 2012.

Lossin C, Shi X, Rogawski MA, Hirose S. Compromised function in the Na(v)1.2 Dravet syndrome mutation R1312T. Neurobiol Dis. 2012 Sep;47(3):378-84.

Cao Z, Hulsizer S, Tassone F, Tang HT, Hagerman RJ, Rogawski MA, Hagerman PJ, Pessah IN. Clustered burst firing in FMR1 premutation hippocampal neurons: amelioration with allopregnanolone. Hum Mol Genet. 2012 Jul 1;21(13):2923-35.

Dhir A, Lossin C, Rogawski MA. Propofol hemisuccinate suppresses cortical spreading depression. Neurosci Lett. 2012 Apr 11;514(1):67-70.

Zolkowska D, Banks CN, Dhir A, Inceoglu B, Sanborn JR, McCoy MR, Bruun DA, Hammock BD, Lein PJ, Rogawski MA. Characterization of seizures induced by acute and repeated exposure to tetramethylenedisulfotetramine. J Pharmacol Exp Ther. 2012 May;341(2):435-46.

Dhir A, Rogawski MA. Role of neurosteroids in the anticonvulsant activity of midazolam. Br J Pharmacol. 2012 Apr;165(8):2684-91.
Rogawski MA, Federoff HJ. Disclosure of clinical trial results when product development is abandoned. Sci Transl Med. 2011 Sep 28;3(102):102cm29.

Stafstrom CE, Arnason BG, Baram TZ, Catania A, Cortez MA, Glauser TA, Pranzatelli MR, Riikonen R, Rogawski MA, Shinnar S, Swann JW. Treatment of infantile spasms: emerging insights from clinical and basic science perspectives. J Child Neurol. 2011 Nov;26(11):1411-21.
</span></span></p><div><span style="font-family: arial, helvetica, sans-serif; font-size: 12px;">Fritsch B, Stott JJ, Donofrio JJ, Rogawski MA. Treatment of early and late kainic-acid induced status epilepticus with the noncompetitive AMPA receptor antagonist GYKI 52466. </span><em style="font-family: arial, helvetica, sans-serif; font-size: 12px;">Epilepsia</em><span style="font-family: arial, helvetica, sans-serif; font-size: 12px;"> 51:108&ndash;117, 2010.</span></div><p><span style="font-family: arial, helvetica, sans-serif; font-size: 12px;">Runyon SP, Orr M, Navarro HA, Kepler JA, Rogawski MA, Kaminski RM, Cook CE. 17β-Nitro-5α-androstan-3α-ol and its 3β-methyl derivative: neurosteroid analogs with potent anticonvulsant and anxiolytic activities. </span><em style="font-family: arial, helvetica, sans-serif; font-size: 12px;">European Journal of Pharmacology</em><span style="font-family: arial, helvetica, sans-serif; font-size: 12px;"> 617:68&ndash;73, 2009.</span></p><p><span style="font-family: arial, helvetica, sans-serif; font-size: 12px;">Fritsch B, Qashu F, Figueiredo TH, Aroniadou-Anderjaska V, Rogawski MA, Braga MF. Pathological alterations in GABAergic interneurons and reduced tonic inhibition in the basolateral amygdala during epileptogenesis. </span><em style="font-family: arial, helvetica, sans-serif; font-size: 12px;">Neuroscience</em><span style="font-family: arial, helvetica, sans-serif; font-size: 12px;"> 163:415&ndash;429, 2009.</span></p><p><span style="font-family: arial, helvetica, sans-serif; font-size: 12px;">Braga MF, Aroniadou-Anderjaska V, Li H, Rogawski MA. Topiramate reduces excitability in the basolateral amygdala by selectively inhibiting GluK1 (GluR5) kainate receptors on interneurons and positively modulating GABA-A receptors on principal neurons.</span><em style="font-family: arial, helvetica, sans-serif; font-size: 12px;">J Pharmacol Exp Ther</em><span style="font-family: arial, helvetica, sans-serif; font-size: 12px;"> 330:558&ndash;566, 2009.</span></p><p><span style="font-family: arial, helvetica, sans-serif; font-size: 12px;">Rogawski MA. Convection-enhanced delivery in the treatment of epilepsy. </span><em style="font-family: arial, helvetica, sans-serif; font-size: 12px;">Neurotherapeutics</em><span style="font-family: arial, helvetica, sans-serif; font-size: 12px;"> 6:344&ndash;351, 2009.</span></p><p><span style="font-family: arial, helvetica, sans-serif; font-size: 12px;">Reddy DS, Rogawski MA. Neurosteroid replacement therapy for catamenial epilepsy. </span><em style="font-family: arial, helvetica, sans-serif; font-size: 12px;">Neurotherapeutics</em><span style="font-family: arial, helvetica, sans-serif; font-size: 12px;"> 6:392&ndash;401, 2009.</span></p><p><span style="font-family: arial, helvetica, sans-serif; font-size: 12px;">Biagini G, Longo D, Baldelli E, Zoli M, Rogawski MA Bertazzoni G, Avoli M. Neurosteroids and epileptogenesis in the pilocarpine model: Evidence for a relationship between P450scc induction and length of the latent period. </span><em style="font-family: arial, helvetica, sans-serif; font-size: 12px;">Epilepsia</em><span style="font-family: arial, helvetica, sans-serif; font-size: 12px;"> 50(Suppl. 1):53&ndash;58, 2009.</span></p><p><span style="font-family: arial, helvetica, sans-serif; font-size: 12px;">Rogawski MA. Antiepileptic drugs and migraine. In, </span><em style="font-family: arial, helvetica, sans-serif; font-size: 12px;">Innovative drug development for headache disorders (Frontiers in Headache Research Series)</em><span style="font-family: arial, helvetica, sans-serif; font-size: 12px;"> (Olesen J and Ramadan N, eds.), Oxford University Press, pp. 153&ndash;178, 2008.</span></p><p><span style="font-family: arial, helvetica, sans-serif; font-size: 12px;">Rogawski MA. Brivaracetam: a rational drug discovery success story. </span><em style="font-family: arial, helvetica, sans-serif; font-size: 12px;">British Journal of Pharmacology</em><span style="font-family: arial, helvetica, sans-serif; font-size: 12px;"> 154:1555&ndash;1557, 2008</span></p><p><span style="font-family: arial, helvetica, sans-serif; font-size: 12px;">Rogawski MA. Common pathophysiologic mechanisms in migraine and epilepsy. </span><em style="font-family: arial, helvetica, sans-serif; font-size: 12px;">Archives of Neurology</em><span style="font-family: arial, helvetica, sans-serif; font-size: 12px;"> 65:709&ndash;714, 2008.</span></p><p><span style="font-family: arial, helvetica, sans-serif; font-size: 12px;">Rogawski MA, Johnson MR. Intrinsic severity as a determinant of antiepileptic drug refractoriness. </span><em style="font-family: arial, helvetica, sans-serif; font-size: 12px;">Epilepsy Currents</em><span style="font-family: arial, helvetica, sans-serif; font-size: 12px;"> 8:127&ndash;130, 2008.</span></p><p><span style="font-family: arial, helvetica, sans-serif; font-size: 12px;">Rogawski MA, Bazil CW. New molecular targets for antiepileptic drugs: α2δ, SV2A, and Kv7/KCNQ/M potassium channels. </span><em style="font-family: arial, helvetica, sans-serif; font-size: 12px;">Current Neurology and Neuroscience Reports</em><span style="font-family: arial, helvetica, sans-serif; font-size: 12px;"> 8:345&ndash;352, 2008.</span></p><p><span style="font-family: arial, helvetica, sans-serif; font-size: 12px;">Macdonald RL, Rogawski MA. Cellular effects of antiepileptic drugs. In, </span><em style="font-family: arial, helvetica, sans-serif; font-size: 12px;">Epilepsy: A Comprehensive Textbook, Second Edition</em><span style="font-family: arial, helvetica, sans-serif; font-size: 12px;"> (Engel J, Jr. and Pedley TA, eds.), Wolters Kluwer/Lippincott Williams &amp; Wilkins, Philadelphia, pp. 1433&ndash;1445, 2008.</span></p><p><span style="font-family: arial, helvetica, sans-serif; font-size: 12px;">Meldrum BS, Rogawski MA. Molecular targets for antiepileptic drug development. </span><em style="font-family: arial, helvetica, sans-serif; font-size: 12px;">Neurotherapeutics</em><span style="font-family: arial, helvetica, sans-serif; font-size: 12px;"> 4:18&ndash;61, 2007.</span></p><p><span style="font-family: arial, helvetica, sans-serif; font-size: 12px;">Hartman AL, Gasior M, Vining EPG, Rogawski MA. Neuropharmacology of the ketogenic diet. </span><em style="font-family: arial, helvetica, sans-serif; font-size: 12px;">Pediatric Neurology</em><span style="font-family: arial, helvetica, sans-serif; font-size: 12px;"> 36:281&ndash;292, 2007.</span></p><p><span style="font-family: arial, helvetica, sans-serif; font-size: 12px;">Theodore WH, Rogawski MA. Epilepsy: mechanisms of drug action and clinical treatment. In, </span><em style="font-family: arial, helvetica, sans-serif; font-size: 12px;">Handbook of Contemporary Neuropharmacology</em><span style="font-family: arial, helvetica, sans-serif; font-size: 12px;"> (Sibley DR, Hanin I, Kuhar M and Skolnick P, eds.), John Wiley &amp; Sons, Hoboken, New Jersey, pp. 403&ndash;441, 2007.</span></p><p><span style="font-family: arial, helvetica, sans-serif; font-size: 12px;">N&#39;Gouemo P, Rogawski MA. Alcohol withdrawal seizures. In, </span><em style="font-family: arial, helvetica, sans-serif; font-size: 12px;">Models of Seizures and Epilepsy</em><span style="font-family: arial, helvetica, sans-serif; font-size: 12px;"> (Pitkänen A, Schwartzkroin PA&nbsp;and Moshé SL, eds.), Elsevier Academic Press, Amsterdam, pp. 161&ndash;177, 2006.</span></p><p><span style="font-family: arial, helvetica, sans-serif; font-size: 12px;">Biagini G, Baldelli E, Longo D, Pradelli L, Zini I, Rogawski MA, Avoli M. Endogenous neurosteroids modulate epileptogenesis in a model of temporal lobe epilepsy. </span><em style="font-family: arial, helvetica, sans-serif; font-size: 12px;">Experimental Neurology</em><span style="font-family: arial, helvetica, sans-serif; font-size: 12px;"> 201:519&ndash;524, 2006.</span></p><p><span style="font-family: arial, helvetica, sans-serif; font-size: 12px;">Rogawski MA. Diverse mechanisms of antiepileptic drugs in the development pipeline. </span><em style="font-family: arial, helvetica, sans-serif; font-size: 12px;">Epilepsy Research</em><span style="font-family: arial, helvetica, sans-serif; font-size: 12px;"> 69:273&ndash;294, 2006.</span></p><p>&nbsp;</p><p><strong>Full text (pdf) versions of recent publications are available <a href="http://works.bepress.com/michael_rogawski/"><u>here</u></a>.</strong></p... id="badgeCont972872"><script src='http://labs.researcherid.com/mashlets?el=badgeCont972872&amp;mashlet=bad...

Other Affiliations: 

Department of Neurology, UC Davis Health System

UC Davis CounterACT Center of Excellence

Current Students: 
<p>Emir Leal Leon</p> <p>Pearl Chen</p>
Postdocs and Research Personnel: 
<p>Abdul Wahab, Ph.D.</p>
Staff Members: 
<p>Christoph Lossin, Ph.D.</p> <p>Dorota Zolkowska, M.D., Ph.D.</p> <p>Ashish Dhir, Ph.D.</p> <p>Chun-Yi "Jimmy" Wu, Ph.D.</p> <p>Daniel Feldman, Ph.D.</p> <p>Lisa Olsen</p>

Current Students

Name Phone Email
Emir Leal Leon
Pearl Chen

Postdocs and Research Personnel

Name Current Position Title Phone Email
Abdul Wahab, Ph.D.

Staff Members

Name Title Phone Email
Christoph Lossin, Ph.D.
Dorota Zolkowska, M.D., Ph.D.
Ashish Dhir, Ph.D.
Chun-Yi "Jimmy" Wu, Ph.D.
Daniel Feldman, Ph.D.
Lisa Olsen